139 related articles for article (PubMed ID: 34165783)
1. Impact of t(11;14) as a sole and concomitant abnormality on outcomes in multiple myeloma.
Bal S; Giri S; Godby KN; Costa LJ
Br J Haematol; 2021 Oct; 195(1):e113-e116. PubMed ID: 34165783
[No Abstract] [Full Text] [Related]
2. Natural history of multiple myeloma patients refractory to venetoclax: A single center experience.
Maples KT; Nooka AK; Gupta V; Joseph NS; Heffner LT; Hofmeister C; Dhodapkar M; Matulis SM; Lonial S; Boise LH; Kaufman JL
Am J Hematol; 2021 Mar; 96(3):E68-E71. PubMed ID: 33275813
[No Abstract] [Full Text] [Related]
3. Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14).
Touzeau C; Le Gouill S; Mahé B; Boudreault JS; Gastinne T; Blin N; Caillon H; Dousset C; Amiot M; Moreau P
Haematologica; 2017 Mar; 102(3):e112-e114. PubMed ID: 28057737
[No Abstract] [Full Text] [Related]
4. Secondary plasma cell leukaemia treated with single agent venetoclax.
Glavey SV; Flanagan L; Bleach R; Kelly C; Quinn J; Ní Chonghaile T; Murphy P
Br J Haematol; 2020 Aug; 190(4):e242-e245. PubMed ID: 32525557
[No Abstract] [Full Text] [Related]
5. Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative Trials.
Avigan ZM; Joshua Richter Md
Oncology (Williston Park); 2024 Jun; 38(6):239-241. PubMed ID: 38899981
[TBL] [Abstract][Full Text] [Related]
6. Double-hit myeloma with IGH/MYC and IGH/CCND1 translocations.
Ji M; Jang S; Lee JH; Seo EJ
Ann Hematol; 2013 Aug; 92(8):1129-31. PubMed ID: 23307601
[No Abstract] [Full Text] [Related]
7. The t(11;14) (q13;q32) in multiple myeloma cell line KMS12 has its 11q13 breakpoint 330 kb centromeric from the cyclin D1 gene.
Vaandrager JW; Kluin P; Schuuring E
Blood; 1997 Jan; 89(1):349-50. PubMed ID: 8978314
[No Abstract] [Full Text] [Related]
8. IgH translocation with undefined partners is associated with superior outcome in multiple myeloma patients.
Mao XH; Zhuang JL; Zhao DD; Li XQ; Du X; Hao M; Xu Y; Yan YT; Liu JH; Fan HS; Sui WW; Deng SH; Li CW; Zhao JW; Yi SH; Du CX; Zou DH; Li ZJ; Zhao YZ; Zhan FH; Tai YT; Fang BJ; Song YP; Wang JX; Anderson KC; Qiu LG; An G
Eur J Haematol; 2020 Sep; 105(3):326-334. PubMed ID: 32421883
[TBL] [Abstract][Full Text] [Related]
9. A subset of CD20(+) MM patients without the t(11;14) are associated with poor prognosis and a link to aberrant expression of Wnt signaling.
Liu J; Gu Z; Yang Y; Wendlandt E; Xu H
Hematol Oncol; 2014 Dec; 32(4):215-7. PubMed ID: 24408089
[No Abstract] [Full Text] [Related]
10. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma.
Touzeau C; Dousset C; Le Gouill S; Sampath D; Leverson JD; Souers AJ; Maïga S; Béné MC; Moreau P; Pellat-Deceunynck C; Amiot M
Leukemia; 2014 Jan; 28(1):210-2. PubMed ID: 23860449
[No Abstract] [Full Text] [Related]
11. The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Cook G; Royle KL; O'Connor S; Cairns DA; Ashcroft AJ; Williams CD; Hockaday A; Cavenagh JD; Snowden JA; Ademokun D; Tholouli E; Andrews VE; Jenner M; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Pratt G; Drayson MT; Brown JM; Morris TCM;
Br J Haematol; 2019 May; 185(3):450-467. PubMed ID: 30729512
[TBL] [Abstract][Full Text] [Related]
12. Venetoclax plus bortezomib and dexamethasone in heavily pretreated end-stage myeloma patients without t(11;14): A real-world cohort.
Jelinek T; Popkova T; Duras J; Mihalyova J; Kascak M; Benkova K; Plonkova H; Cerna L; Koristek Z; Simicek M; Hajek R
Hematol Oncol; 2020 Aug; 38(3):412-414. PubMed ID: 32323881
[No Abstract] [Full Text] [Related]
13. Characterization and use of the novel human multiple myeloma cell line MC-B11/14 to study biological consequences of CRISPR-mediated loss of immunoglobulin A heavy chain.
Walters DK; Arendt BK; Tschumper RC; Wu X; Jelinek DF
Exp Hematol; 2018 Jan; 57():42-49.e1. PubMed ID: 29030084
[TBL] [Abstract][Full Text] [Related]
14. Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence.
Kitadate A; Terao T; Narita K; Ikeda S; Takahashi Y; Tsushima T; Miura D; Takeuchi M; Takahashi N; Matsue K
Cancer Sci; 2021 Sep; 112(9):3645-3654. PubMed ID: 34288263
[TBL] [Abstract][Full Text] [Related]
15. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors.
Avet-Loiseau H; Gerson F; Magrangeas F; Minvielle S; Harousseau JL; Bataille R;
Blood; 2001 Nov; 98(10):3082-6. PubMed ID: 11698294
[TBL] [Abstract][Full Text] [Related]
16. The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization.
Nishida K; Tamura A; Nakazawa N; Ueda Y; Abe T; Matsuda F; Kashima K; Taniwaki M
Blood; 1997 Jul; 90(2):526-34. PubMed ID: 9226151
[TBL] [Abstract][Full Text] [Related]
17. Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations.
Pawlyn C; Melchor L; Murison A; Wardell CP; Brioli A; Boyle EM; Kaiser MF; Walker BA; Begum DB; Dahir NB; Proszek P; Gregory WM; Drayson MT; Jackson GH; Ross FM; Davies FE; Morgan GJ
Blood; 2015 Jan; 125(5):831-40. PubMed ID: 25428216
[TBL] [Abstract][Full Text] [Related]
18. Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by double-color fluorescent in situ hybridization.
Finelli P; Fabris S; Zagano S; Baldini L; Intini D; Nobili L; Lombardi L; Maiolo AT; Neri A
Blood; 1999 Jul; 94(2):724-32. PubMed ID: 10397739
[TBL] [Abstract][Full Text] [Related]
19. 14q32 chromosomal translocations: a hallmark of plasma cell dyscrasias?
Avet-Loiseau H; Minvielle S; Mellerin MP; Magrangeas F; Bataille R
Hematol J; 2000; 1(5):292-4. PubMed ID: 11920205
[No Abstract] [Full Text] [Related]
20. Translocation of the IgH locus is nearly ubiquitous in multiple myeloma as detected by immuno-FISH.
Boersma-Vreugdenhil GR; Peeters T; Bast BJ; Lokhorst HM
Blood; 2003 Feb; 101(4):1653. PubMed ID: 12560243
[No Abstract] [Full Text] [Related]
[Next] [New Search]
